Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.
Dr. Zheng is applying a quantitative glioma cell differentiation reporter system, in conjunction with his customized epigenetic RNAi library, to execute a comprehensive study of the epigenetic modifiers whose suppression will promote glioma cell differentiation and thus reduce tumorigenic potential. The fact that epigenetic aberrations, unlike genetic alterations, are potentially reversible makes the initiative promising and therapeutically relevant. It is his belief that the proposed studies will elaborate a list of novel therapeutic targets that can be enrolled into productive drug discovery and development efforts against malignant gliomas.